Your lab results came back normal. Your doctor says you're fine. You leave the appointment reassured. You shouldn't be.
“Normal” on a standard blood panel doesn't mean healthy. It means you're not far enough from average to trigger a callback. The reference ranges printed on your results were built by measuring a large cross-section of the population, which includes people with pre-diabetes, subclinical inflammation, early-stage cardiovascular disease, and metabolic dysfunction they haven't been diagnosed with yet. You're being compared to them.
Clinical labs define “normal” as the range containing the middle 95% of test results from that reference population. If the population is metabolically unhealthy (and by most measures, the average American is), then normal is a description of disease in slow motion, not a certificate of health.
Longevity medicine approaches this differently. Instead of asking “where does most of the population land?” it asks: where do long-lived, metabolically healthy individuals cluster? Those two questions produce very different answers.
The Gap Between Normal and Optimal
The differences are not subtle. On several key markers, the longevity-optimal target is 30–50% tighter than what your lab report flags as acceptable. A result your doctor calls good can still put you in the suboptimal zone for long-term health outcomes.
Here's how the numbers compare across the markers that matter most for healthspan:
| Biomarker | Clinical “Normal” | Longevity Optimal |
|---|---|---|
| HbA1c | <5.7% | 4.0–5.0% |
| Fasting Insulin | <25 µIU/mL | 2–5 µIU/mL |
| Fasting Glucose | 70–99 mg/dL | 72–85 mg/dL |
| LDL Cholesterol | <100 mg/dL | <70 mg/dL |
| ApoB | <90 mg/dL | <60 mg/dL |
| Triglycerides | <150 mg/dL | <100 mg/dL |
| hs-CRP | <3.0 mg/L | <1.0 mg/L |
| Homocysteine | <15 µmol/L | 5–8 µmol/L |
| Vitamin D | >30 ng/mL | 40–80 ng/mL |
| eGFR | >90 mL/min | >100 mL/min |
| ALT | <40 U/L | 10–25 U/L |
Look at fasting insulin. The clinical upper limit is 25 µIU/mL, meaning you could have insulin at five times the longevity-optimal level and your doctor would consider it normal. Insulin resistance typically develops years before glucose rises, yet most annual physicals don't even order a fasting insulin panel.
Why Fasting Insulin Is the Most Important Test You're Not Getting
HbA1c catches the downstream effect of chronically elevated blood sugar. Fasting insulin catches the problem upstream, often years or even a decade before glucose abnormalities appear. When insulin climbs to compensate for early resistance, glucose may still look perfectly fine at 88 mg/dL. Your doctor sees normal. Your pancreas is working overtime.
The longevity-optimal target of 2–5 µIU/mL reflects where metabolically healthy, long-lived individuals tend to cluster. At that level, your cells are responding efficiently to insulin signals. At 18 µIU/mL (still “normal”), insulin resistance is likely well underway.
Request it specifically. It's rarely included in a standard metabolic panel.
ApoB vs. LDL: The Better Cardiovascular Marker
LDL cholesterol has been the dominant cardiovascular risk marker for decades. It's also an imperfect one. LDL measures the total cholesterol carried in low-density lipoprotein particles but says nothing about how many particles there are. A small number of large, cholesterol-rich particles can produce the same LDL number as a large number of small, dense particles. The small, dense ones are far more likely to cause arterial damage.
ApoB counts the particles directly. Each LDL particle carries exactly one ApoB protein. An elevated ApoB with a normal LDL is a warning sign that standard cholesterol panels miss entirely. The longevity target of <60 mg/dL is stricter than most cardiology guidelines, and for good reason. The research on lifetime cardiovascular risk increasingly points to cumulative ApoB exposure as the primary driver of arterial buildup. Lower for longer.
The Inflammation Markers Most People Ignore
hs-CRP (high-sensitivity C-reactive protein) measures inflammation in your body. The clinical cutoff of 3.0 mg/L identifies acute inflammatory events. The longevity target of <1.0 mg/L identifies chronic low-grade inflammation: the kind that quietly accelerates aging across virtually every organ system without producing obvious symptoms.
Homocysteine sits in a similar blind spot. It's an amino acid byproduct linked to cardiovascular disease, cognitive decline, and DNA damage. Clinical labs flag it only above 15 µmol/L. The longevity-optimal range is 5–8 µmol/L. If you're at 12, your doctor sees nothing. If you understand the research, you have work to do.
Homocysteine responds directly to B-vitamin intake. B6, B12, and folate are what break it down. It's one of the most correctable markers on this list.
Vitamin D: The 30 ng/mL Floor Is Not a Target
The clinical sufficiency threshold for Vitamin D is 30 ng/mL. This was set to prevent deficiency diseases like rickets, not to optimize immune function, bone density, cardiovascular health, or the many other processes Vitamin D regulates.
The longevity-optimal range is 40–80 ng/mL. Studies on populations with naturally high sun exposure, who consistently show better all-cause mortality outcomes, cluster in this range. Someone at 32 ng/mL will be told their Vitamin D is fine. There's still a meaningful gap between fine and optimal.
How to Actually Interpret Your Results
The most useful way to read your bloodwork isn't binary (normal/abnormal). It's a four-tier system:
- OptimalWithin the longevity-optimal range. This is the target.
- NormalClinically fine, but outside the longevity-optimal zone. Your doctor says nothing. You should pay attention.
- AttentionOutside the clinical reference range. Warrants investigation and likely intervention.
- CriticalMore than 20% outside clinical range. Requires immediate action.
This distinction matters because most people in the “Normal” zone assume they have nothing to address. They're not sick, so they don't act. Longevity medicine focuses on this zone specifically, because the gap between Normal and Optimal is where aging happens before you can see it.
The Retesting Schedule That Actually Matters
A single snapshot is useful. A trend is what drives decisions. Retest every 3–6 months: frequent enough to detect trajectory, not so frequent that normal biological variation looks like a trend.
With regular retesting, you're not just asking “where am I?” You're asking “which direction am I moving, and how fast?” That second question is measurably more predictive of long-term health outcomes than any single result.
A fasting insulin that drops from 14 to 8 µIU/mL over six months after a dietary change tells you something no single test result can. An HbA1c trending upward from 5.1% to 5.4% over two years, while still “normal,” is a warning you should act on now. Not at 5.7% when your doctor finally has a code to bill against.
What to Do With This
Request a full panel the next time you get bloodwork. Specifically ask for fasting insulin and ApoB; they're rarely ordered without a specific request. Ask for hs-CRP and homocysteine if cardiovascular risk is a concern. Get Vitamin D tested twice a year if you live at a northern latitude.
Then interpret the results against longevity-optimal ranges, not just the reference values on the printout. Your goal isn't to pass the test. Your goal is to understand where you actually stand and which direction you're heading.
Mallet tracks 45 biomarkers against longevity-optimal ranges, not just clinical thresholds. Upload your bloodwork and every marker gets mapped to a four-tier status: Optimal, Normal, Attention, or Critical. You'll see exactly where you stand, what to address first, and how your results trend over time. The AI connects your bloodwork directly to your supplement protocol, nutrition targets, and training program. Get early access →